Investment Thesis
AN2 Therapeutics is a pre-revenue biopharmaceutical company burning substantial cash with negative operating cash flow of -$29.8M and minimal runway given $19.9M in cash reserves. The company is unprofitable with no revenue generation, negative ROE of -66.3%, and deteriorating financial health despite maintaining a strong balance sheet relative to liabilities.
ANTX Strengths
- Excellent liquidity position with current ratio of 6.87x and $19.9M cash reserves
- No long-term debt burden with debt/equity ratio of 0.00x, reducing financial risk
- Relatively strong stockholders' equity of $53.1M providing balance sheet cushion
- Significant insider activity with 21 Form 4 filings suggesting management engagement
ANTX Risks
- Pre-revenue stage with zero commercial product income and N/A gross margins indicating no commercialization
- Severe negative cash burn of -$29.8M annually with only ~8 months of cash runway at current burn rate
- Ongoing operating losses of -$38.1M with negative ROE (-66.3%) and ROA (-56.8%), destroying shareholder value
- Clinical/development stage company faces binary outcomes; no evidence of regulatory approval or revenue inflection
- Diluted EPS of -$1.16 reflects heavy shareholder dilution from equity financing to fund ongoing losses
Key Metrics to Watch
- Cash runway and burn rate trajectory; critical for assessing survival timeline
- Clinical trial progress and regulatory milestones for pipeline candidates
- Operating expense control and path to revenue generation or strategic alternatives
ANTX Financial Metrics
ANTX Profitability Ratios
ANTX Balance Sheet & Liquidity
ANTX 5-Year Financial Trend
5-Year Trend Summary: AN2 Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.72 indicates the company is currently unprofitable.
ANTX Growth Metrics (YoY)
ANTX Capital Allocation
ANTX SEC Filings
Access official SEC EDGAR filings for AN2 Therapeutics, Inc. (CIK: 0001880438)